Molecular glue degraders are a class of small molecules designed to selectively degrade proteins that contribute to disease, including those involved in cancer growth and immune system dysfunction, according to a Jan. 23 news release from the drugmaker.
Under the agreement, AbbVie will provide an upfront payment to Neomorph, which is also eligible for up to $1.64 billion in option fees and milestone payments, in addition to tiered royalties on any future product sales.
The collaboration combines AbbVie’s established capabilities in oncology and immunology with Neomorph’s molecular glue platform, the release said.
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
